Safety profile
| AEs ≥10%, n (%) . | Cohort C (N = 40) . | ||
|---|---|---|---|
| Any grade . | Grade 3/4 . | Grade 5 . | |
| Hematologic | |||
| Neutropenia | 28 (70.0) | 26 (65.0) | 0 |
| Anemia | 20 (50.0) | 14 (35.0) | 0 |
| Lymphopenia | 18 (45.0) | 17 (42.5) | 0 |
| Thrombocytopenia | 18 (45.0) | 12 (30.0) | 0 |
| Nonhematologic | |||
| Infections and infestations | 28 (70.0) | 13 (32.5) | 4 (10.0) |
| CRS | 26 (65.0) | 0 | 0 |
| Diarrhea | 15 (37.5) | 1 (2.5) | 0 |
| Constipation | 15 (37.5) | 0 | 0 |
| Pyrexia | 14 (35.0) | 0 | 0 |
| Injection site erythema | 13 (32.5) | 0 | 0 |
| Arthralgia | 11 (27.5) | 0 | 0 |
| COVID-19 | 10 (25.0) | 5 (12.5) | 4 (10.0) |
| Dyspnea | 10 (25.0) | 2 (5.0) | 0 |
| Headache | 10 (25.0) | 0 | 0 |
| Asthenia | 9 (22.5) | 2 (5.0) | 0 |
| Musculoskeletal chest pain | 9 (22.5) | 0 | 0 |
| Bone pain | 8 (20.0) | 1 (2.5) | 0 |
| Fatigue | 8 (20.0) | 1 (2.5) | 0 |
| Pain in extremity | 8 (20.0) | 1 (2.5) | 0 |
| Cough | 8 (20.0) | 0 | 0 |
| Hyponatremia | 7 (17.5) | 3 (7.5) | 0 |
| Alanine aminotransferase increased | 7 (17.5) | 1 (2.5) | 0 |
| Aspartate aminotransferase increased | 7 (17.5) | 1 (2.5) | 0 |
| Back pain | 7 (17.5) | 0 | 0 |
| Decreased appetite | 6 (15.0) | 1 (2.5) | 0 |
| Hypocalcemia | 6 (15.0) | 1 (2.5) | 0 |
| Hypogammaglobulinemia | 6 (15.0) | 0 | 0 |
| Injection site pruritus | 6 (15.0) | 0 | 0 |
| Hypokalemia | 5 (12.5) | 2 (5.0) | 0 |
| Acute kidney injury | 4 (10.0) | 2 (5.0) | 1 (2.5) |
| Cardiac arrest | 1 (2.5) | 0 | 1 (2.5) |
| Cardiac failure | 1 (2.5) | 0 | 1 (2.5) |
| Coronary artery dissection | 1 (2.5) | 0 | 1 (2.5) |
| AEs ≥10%, n (%) . | Cohort C (N = 40) . | ||
|---|---|---|---|
| Any grade . | Grade 3/4 . | Grade 5 . | |
| Hematologic | |||
| Neutropenia | 28 (70.0) | 26 (65.0) | 0 |
| Anemia | 20 (50.0) | 14 (35.0) | 0 |
| Lymphopenia | 18 (45.0) | 17 (42.5) | 0 |
| Thrombocytopenia | 18 (45.0) | 12 (30.0) | 0 |
| Nonhematologic | |||
| Infections and infestations | 28 (70.0) | 13 (32.5) | 4 (10.0) |
| CRS | 26 (65.0) | 0 | 0 |
| Diarrhea | 15 (37.5) | 1 (2.5) | 0 |
| Constipation | 15 (37.5) | 0 | 0 |
| Pyrexia | 14 (35.0) | 0 | 0 |
| Injection site erythema | 13 (32.5) | 0 | 0 |
| Arthralgia | 11 (27.5) | 0 | 0 |
| COVID-19 | 10 (25.0) | 5 (12.5) | 4 (10.0) |
| Dyspnea | 10 (25.0) | 2 (5.0) | 0 |
| Headache | 10 (25.0) | 0 | 0 |
| Asthenia | 9 (22.5) | 2 (5.0) | 0 |
| Musculoskeletal chest pain | 9 (22.5) | 0 | 0 |
| Bone pain | 8 (20.0) | 1 (2.5) | 0 |
| Fatigue | 8 (20.0) | 1 (2.5) | 0 |
| Pain in extremity | 8 (20.0) | 1 (2.5) | 0 |
| Cough | 8 (20.0) | 0 | 0 |
| Hyponatremia | 7 (17.5) | 3 (7.5) | 0 |
| Alanine aminotransferase increased | 7 (17.5) | 1 (2.5) | 0 |
| Aspartate aminotransferase increased | 7 (17.5) | 1 (2.5) | 0 |
| Back pain | 7 (17.5) | 0 | 0 |
| Decreased appetite | 6 (15.0) | 1 (2.5) | 0 |
| Hypocalcemia | 6 (15.0) | 1 (2.5) | 0 |
| Hypogammaglobulinemia | 6 (15.0) | 0 | 0 |
| Injection site pruritus | 6 (15.0) | 0 | 0 |
| Hypokalemia | 5 (12.5) | 2 (5.0) | 0 |
| Acute kidney injury | 4 (10.0) | 2 (5.0) | 1 (2.5) |
| Cardiac arrest | 1 (2.5) | 0 | 1 (2.5) |
| Cardiac failure | 1 (2.5) | 0 | 1 (2.5) |
| Coronary artery dissection | 1 (2.5) | 0 | 1 (2.5) |